China’s Aoxing, U.S.’s American Oriental Pair To Market Painkillers
This article was originally published in PharmAsia News
Executive Summary
China's Aoxing Pharmaceutical has signed an agreement with Oriental Bioengineering of the United States to develop and market painkillers and narcotics. The deal calls for American Oriental buying a 38 percent share of Aoxing for $18 million. Aoxing recently completed its acquisition of Shijazhuang Lerentang Pharmaceutical, also of China. Shijazhuang specializes in pain-management products. (Click here for more